Navigation Links
AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
Date:9/5/2012

IRVINE, Calif., Sept. 5, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, will be a presenting company at the Rodman & Renshaw 14th Annual Healthcare and Global Investment Conference to be held in New York City from September 9 -11, 2012 at the Waldorf-Astoria.  Mark Selawski, CFO of AtheroNova, will present at 3:15pm ET on Tuesday, September 11.

Mr. Selawski will discuss exciting near term milestones for AHRO-001, the Company's lead compound for the regression of atherosclerotic plaque, as well as the Company's pipeline and development plans. 

In addition to the presentation, Mr. Selawski will be available to meet with analysts, industry executives and investors in one-on-one meetings.  Those interested in meeting with Mr. Selawski for a one-on-one discussion during the Conference are encouraged to contact the Company directly at info@atheronova.com.

About AtheroNova

AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova Operations, Inc., is an early stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits.  The Company's focus on compounds to reduce or eliminate atherosclerotic plaque deposits addresses the most lucrative segments of the multi-billion dollar prescription drug market: cardiovascular disease and stroke prevention. www.AtheroNova.com

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Exa
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AtheroNova Releases 2011 Financial Results
2. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
3. AtheroNova Announces a New Board Member
4. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
5. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
6. Onyx Pharmaceuticals To Present At Upcoming Investor Conferences
7. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
8. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
9. Insmed to Present at Stifel Nicolaus 2012 Healthcare Conference
10. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics: Twease.org
11. Life Technologies to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... NASA’s MESSENGER has just celebrated its 10 year ... have one of its latch valves, V27200-818, operating onboard ... investigation of the planet Mercury. It is only the ... provided a vast amount of information and images of ... utilize solenoids that also include permanent magnets to maintain ...
(Date:9/17/2014)... 17, 2014 The Alliance ... a multi-stakeholder non-profit collaborative building a global system ... research, today announced Phase 3 of its Site ... , Amir H. Kalali, Vice-President, Global Head, Neuroscience ... President, Compliance and Quality Integration (CQI) Consulting will ...
(Date:9/16/2014)... 16, 2014 This report analyzes the worldwide markets ... Software, Hardware, and Biocontent. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are provided for ... is provided for these markets. Market data and analytics are ...
(Date:9/16/2014)... SAN DIEGO , Sept. 16, 2014  Biocom, ... life science community, recognizes the 9 th ... to the value of IT technologies in improving our ... California is one of the world,s most ... from EHRs to mobile health applications to genomic testing ...
Breaking Biology Technology:Global Standards Initiative for Clinical Research Sites Advances 2Global Standards Initiative for Clinical Research Sites Advances 3Global Standards Initiative for Clinical Research Sites Advances 4Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23Biocom Recognizes National Health IT Week 2
... Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) ("Oncolytics") ... Patent 7,374,752 entitled "Reovirus for the Treatment ... compositions,which comprise various recombinant reoviruses., "This ... protection for,reovirus compositions in the United States," ...
... of Two-Phase Examination of U.S. Asthma Control, RESEARCH ... half of adult Americans with asthma and more than ... nationally representative survey do,not have their disease well controlled, ... at the International Conference of the American,Thoracic Society meeting ...
... 20 CellCyte Genetics,Corporation (CellCyte) (OTC Bulletin ... H. Traverse, M.D., FACC, FAHA, to its ... is an interventional,cardiologist with the Minneapolis Heart ... in cardiovascular stem cell clinical,trial research., ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Issuance of 27th U.S. Patent 2Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows 2Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows 3CellCyte Genetics Corp. Appoints Jay H. Traverse to Scientific Advisory Board as Clinical Consultant 2CellCyte Genetics Corp. Appoints Jay H. Traverse to Scientific Advisory Board as Clinical Consultant 3
(Date:9/16/2014)... Philadelphia, PA, September 16, 2014 Schizophrenia is associated ... A growing body of research suggests that the relationship ... effort by patients to use nicotine to self-medicate symptoms ... new study, published in the current issue of ... authors found that the level of nicotine receptors in ...
(Date:9/16/2014)... are responsible for practically all vital functions in ... forward signals, transport particular substances and control immune ... proteins do not function independently of each other, ... examine the protein networks, you find many similarities ... from TUM,s Chair of Plant Systems Biology. "Some ...
(Date:9/15/2014)... microbes influence processes from digestion to disease resistance. Despite ... terrestrial ecosystems on the planet, more is known about ... Smithsonian scientists and colleagues working on Panama,s Barro Colorado ... tree were home to more than 400 different kinds ... contained more than 7,000 different kinds. , Bacteria in ...
Breaking Biology News(10 mins):Smoking and schizophrenia linked by alterations in brain nicotine signals 2Good networkers make prime targets 2Smithsonian scientists discover tropical tree microbiome in Panama 2
... clinical trials to find a successful vaccine against footrot ... with funding of $663,000 from Australian Wool Innovation (AWI) ... place at Monash University,s Australian Research Council Centre of ... University of Sydney. Chief investigator Professor Julian Rood ...
... first oral, broad-spectrum angiogenesis inhibitor, specially formulated through nanotechnology, ... Children,s Hospital Boston. Findings were published online on June ... Because it is nontoxic and can be taken orally, ... preventive therapy for patients at high risk for cancer ...
... NEW YORK (July 1, 2008) -- Clinician-scientists from NewYork-Presbyterian ... important change to guidelines used in the care of ... that following TBI, patients should be given nutritional supplementation ... which they say can improve their chances of survival ...
Cached Biology News:Footrot vaccine closer than ever 2New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers 2New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers 3Following traumatic brain injury, balanced nutrition saves lives 2
EDG-6 (1)...
...
...
... Comments: Ab-1 stains tumor cells of embryonal ... type of germ cell tumors like seminoma. Glandular ... are positive. Luminal and endocrine cells of stomach ... breast are also positive. Epitope: Carbohydrate ...
Biology Products: